ProQR (PRQR)

Executive Summary

ProQR Therapeutics is a clinical-stage biotech company pioneering RNA-based therapies for severe genetic disorders, with a focus on rare retinal diseases and central nervous system conditions. Its lead candidate, sepofarsen, is in Phase 2/3 for Leber Congenital Amaurosis 10 (LCA10), a rare inherited retinal degeneration. Additional programs include QR-1123 for autosomal dominant retinitis pigmentosa (Phase 1/2) and earlier-stage candidates for Fuchs endothelial corneal dystrophy and cystic fibrosis. The company's proprietary RNA modulation platform aims to correct genetic defects at the post-transcriptional level, offering potential treatments for diseases with limited options. ProQR has completed multiple clinical trials and continues to advance its pipeline through public funding and strategic partnerships. Despite recent pipeline setbacks, including the withdrawal of QR-504a, ProQR remains focused on executing its clinical strategy. Upcoming milestones include data readouts from ongoing sepofarsen studies and potential regulatory interactions for LCA10. The company's valuation (~$173M) reflects cautious investor sentiment given the high-risk nature of gene therapy development. However, successful proof-of-concept in the retina programs could unlock significant value. ProQR's cash runway and ability to secure non-dilutive funding will be critical for advancing its pipeline to late-stage trials.

Upcoming Catalysts (preview)

• Q3 2026Sepofarsen Phase 2/3 Data Readout for LCA1035% success
• Q4 2026QR-1123 Phase 1/2 Interim Results for Autosomal Dominant Retinitis Pigmentosa50% success
• H2 2026Potential Partnership or Licensing Deal for CNS Pipeline25% success